Clinical trial results:
An evaluator-blinded multi-center study of combined treatment with Azzalure, Restylane/Emervel filler and Restylane skinbooster as compared to single treatment with either Azzalure alone or Restylane/Emervel filler alone

Summary

EudraCT number	2014-001203-50
Trial protocol	SE
Global end of trial date	17 December 2016
Results information	
Result version number	v1 (current)
This version publication date	13 February 2020
First version publication date	13 February 2020
Summary attachment (see zip file)	Cartier.2019.Repeated full-face aesthetic combination treatment (Cartier.2019.Repeated Full-Face Aesthetic Combination Treatment With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin-Boosting Hyaluronic Acid After Monotherapy With AbobotulinumtoxinA or Hyaluronic Acid Filler.pdf)

Trial information

Trial identification	
Sponsor protocol code	05DF1211
Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02297503
WHO universal trial number (UTN)	-

Notes:

Sponsors	
Sponsor organisation name	Galderma/Q-Med AB
Sponsor organisation address	Seminariegatan 21, Uppsala, Sweden, 75228
Public contact	Medical Affairs Cecilia Skoglund, Galderma/Q-Med AB, +46 18489 1410, cecilia.skoglund@galderma.com
Scientific contact	Medical Affairs Cecilia Skoglund, Galderma/Q-Med AB, +46 18489 1410, cecilia.skoglund@galderma.com

Notes:

Paediatric regulatory details	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 December 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 December 2016
Global end of trial reached?	Yes
Global end of trial date	17 December 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to evaluate if superior global facial aesthetic appearance can be achieved by combined treatment with Azzalure, Restylane/Emervel filler and Restylane skinbooster compared to single treatment with either Azzalure or Restylane/Emervel filler alone

Protection of trial subjects:

N/A

Background therapy:

N/A

Evidence for comparator:

N/A

Actual start date of recruitment	01 July 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 39
Country: Number of subjects enrolled	France: 22
Worldwide total number of subjects	61
EEA total number of subjects	61

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	61
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

First subject first visit: 03 Nov 2014
Last subject last visit: 17 Dec 2016

Pre-assignment

Screening details:

There were no screening failures in this study. Sixty-one subjects were randomized; of these, 60 were treated and one (randomized to treatment Group A) was excluded before treatment. This subject withdrew her consent prior to treatment due to a vasovagal episode.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Assessor[1]

Blinding implementation details:

Independent evaluators (assessors) remained blinded to the treatment arm and to the sequence of subject photographs, i.e. they did not know whether a given photograph was taken after the single or combined treatments.

Arms

Are arms mutually exclusive?	Yes
Arm title	Group A - Azzalure as single treatment

Arm description:

Subjects in Group a received treatment with ≤50 s.U Azzalure as single treatment in glabellar lines. At month 6 and 12, both
groups received combined treatment consisting of ≤50 s.U Azzalure in glabellar lines, ≤2
mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.

Arm type	Experimental
Investigational medicinal product name	Azzalure
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A vial with 125 s.U of Azzalure powder was reconstituted in 0.63 mL NaCl 0.9% before injection (10 s.U per 0.05 mL of reconstituted solution). Azzalure was administered by intra-muscular injection of the glabellar lines; the recommended dose was 50 s.U in five
injection points, one in the procerus and two in each corrugator (10 s.U/0.05 mL in each injection point).

Arm title	Group B - hyaluronic acid filler as single treatment

Arm description:

Subjects in Group B received ≤1 mL hyaluronic acid filler in nasolabial folds/cheeks as single treatment. At month 6 and 12, both groups received combined treatment consisting of ≤50 s.U Azzalure in the glabellar lines, ≤2 mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.

Arm type	Experimental

Investigational medicinal product name	N/A (medical device)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Intradermal use

Dosage and administration details:

A maximum of 1 mL (one syringe) of Restylane or Emervel filler was administered to nasolabial folds and/or cheeks at initial baseline treatment, and ≤2 mL was injected at month 6 and month 12.

Notes:

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: An open study design served the study objectives adequately, but to strengthen the results, photograph evaluators remained blinded to the treatment arm and to the sequence of photographs, i.e. they did not know whether a given photograph was taken after the single or combined treatment.

Number of subjects in period 1	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment
Started	30	31
Single treatment	29	31
First combined treatment	28	28
Second combined treatment	28	28
Completed	28	27
Not completed	2	4
Consent withdrawn by subject	1	1
Medical reason	-	1
Pregnancy	-	1
Lost to follow-up	-	1
Exclusion criteria	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Group A - Azzalure as single treatment
Reporting group description:	
Subjects in Group a received treatment with ≤50 s.U Azzalure as single treatment in glabellar lines. At month 6 and 12, both groups received combined treatment consisting of ≤50 s.U Azzalure in glabellar lines, ≤2 mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.	
Reporting group title	Group B - hyaluronic acid filler as single treatment
Reporting group description:	
Subjects in Group B received ≤1 mL hyaluronic acid filler in nasolabial folds/cheeks as single treatment. At month 6 and 12, both groups received combined treatment consisting of ≤50 s.U Azzalure in the glabellar lines, ≤2 mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.	

Reporting group values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment	Total
Number of subjects	30	31	61
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	31	61
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	45.9	43.6	
full range (min-max)	36 to 50	36 to 49	-
Gender categorical Units: Subjects			
Female	30	30	60
Male	0	1	1

End points

End points reporting groups

Reporting group title	Group A - Azzalure as single treatment
Reporting group description:	
Subjects in Group a received treatment with ≤50 s.U Azzalure as single treatment in glabellar lines. At month 6 and 12, both groups received combined treatment consisting of ≤50 s.U Azzalure in glabellar lines, ≤2 mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.	
Reporting group title	Group B - hyaluronic acid filler as single treatment
Reporting group description:	
Subjects in Group B received ≤1 mL hyaluronic acid filler in nasolabial folds/cheeks as single treatment. At month 6 and 12, both groups received combined treatment consisting of ≤50 s.U Azzalure in the glabellar lines, ≤2 mL hyaluronic acid filler in nasolabial folds/cheeks and ≤1 mL Restylane Skinbooster. An additional Skinbooster treatment was given at Month 7.	

Primary: Global facial aesthetic appearance

End point title	Global facial aesthetic appearance
End point description:	
Percentage of subjects that showed a superior global facial aesthetic appearance one month after the first combined treatment than one month after the single treatment, as assessed by blinded evaluation of photographs. Primary and secondary endpoints were defined in the CSP version that was approved for use at the French sites, whereas the Swedish amendment of the protocol did not define primary and secondary endpoints.	
End point type	Primary
End point timeframe:	
Month 1, Month 7	

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	27		
Units: Percentage	74	93		

Statistical analyses

Statistical analysis title	Global facial aesthetic appearance[1]
Comparison groups	Group A - Azzalure as single treatment v Group B - hyaluronic acid filler as single treatment

Number of subjects included in analysis	54
Analysis specification	Pre-specified
Analysis type	superiority[2]
Parameter estimate	Confidence interval
Point estimate	50
Confidence interval	
level	95 %
sides	2-sided
lower limit	50

Notes:

[1] - A low or upper value for the confidence interval may be missing. Values for both the lower and upper limit are expected to be provided with a 2-sided confidence interval.
Justification: Global facial aesthetic appearance was analyzed using a 95% CI for the proportion of subjects for whom the photographs taken 1 month after first combined treatment showed superior global facial aesthetic appearance than the photographs taken after single treatment. The primary objective was to show that the 95% CI was above
50%, no upper limit was defined.
[2] - Global facial aesthetic appearance was analyzed using a 95% CI for the proportion of subjects for whom the photographs taken one month after first combined treatment (Month 7) showed superior global facial aesthetic appearance over the photographs taken after single treatment (Month 1).

Other pre-specified: Global facial aesthetic appearance

End point title	Global facial aesthetic appearance

End point description:

Percentage of subjects showing superior global facial aesthetic appearance after single, first combined and second combined treatment (blinded review of photographs).

End point type	Other pre-specified

End point timeframe:

Month 1, Month 7, Month 13 (one month after each treatment).

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23	25		
Units: Percentage				
Superior Month 1	22	0		
Superior Month 7	22	44		
Superior Month 13	56	56		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Global aesthetic improvement scale - investigator assessment

End point title	Global aesthetic improvement scale - investigator assessment

End point description:

Percentage of subjects assessed as improved (somewhat improved, much improved, and very much improved) on the
Global Aesthetic Improvement Scale (GAIS) by investigators at timepoints Month 1, Month 7 and

Month 13, i.e. one month after single treatment, first and second combined treatment.

End point type	Other pre-specified

End point timeframe:

Month 1, Month 7, Month 13

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: Percentage				
Improved Month 1	100	77		
Improved Month 7	100	68		
Improved Month 13	100	100		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Subject satisfaction with facial appearance

End point title	Subject satisfaction with facial appearance

End point description:

The subjects were asked to answer the question "How satisfied are you today with the appearance of your face?" with "Very/somewhat satisfied", "neither/nor", or "Very/somewhat dissatisfied". Satisfied criteria was fulfilled for those subjects that answered "Very/somewhat satisfied".

End point type	Other pre-specified

End point timeframe:

Baseline, Month 1, Month 7, Month 13

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	29	31		
Units: Percentage				
Satisfied Month 1	55	65		
Satisfied Month 7	82	93		
Satisfied Month 13	86	96		
Satisfied baseline	21	42		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Wrinkle severity glabellar lines at rest - investigator assessment

End point title	Wrinkle severity glabellar lines at rest - investigator assessment

End point description:

The wrinkle severity of Azzalure treated glabellar lines at rest was evaluated by the investigator at all visits. A validated 5-grade photonumeric grading scale was used, where each severity grade was illustrated by as set of photographs.
0 = no glabella lines
1 = mild glabella lines
2 = moderate glabella lines
3 = severe glabella lines
4 = very severe glabella lines
Improvement was defined as going from a higher score to a lower score.

End point type	Other pre-specified

End point timeframe:

Months 7, 9, 12, 13, 15, 18

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	28		
Units: Percentage				
Improved Month 7	75	71		
Improved Month 9	61	57		
Improved Month 12	43	32		
Improved Month 13	86	68		
Improved Month 15	64	52		
Improved Month 18	54	44		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Wrinkle severity glabellar lines at maximum frown - investigator assessment

End point title	Wrinkle severity glabellar lines at maximum frown - investigator assessment

End point description:

The wrinkle severity of Azzalure treated glabellar lines at maximum frown was evaluated by the investigator at all visits. A validated 5-grade photonumeric grading scale was used, where each severity grade was illustrated by as set of photographs.
0 = no glabella lines
1 = mild glabella lines
2 = moderate glabella lines
3 = severe glabella lines
4 = very severe glabella lines
Improvement was defined as going from a higher score to a lower score.

End point type	Other pre-specified

End point timeframe:

Months 7, 9, 12, 13, 15, 18

End point values	Group A - Azzalure as single treatment	Group B - hyaluronic acid filler as single treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28	28		
Units: Percentage				
Month 7	96	100		
Month 9	82	96		
Month 12	54	29		
Month 13	96	100		
Month 15	89	85		
Month 18	68	67		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

2 years, 1 month, 15 days (first enrolment - last completed)

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

Reporting groups

Reporting group title	Group A after single treatment with Azzalure

Reporting group description:

Group A received Azzalure alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the single treatment was given but before the 1st combined treatment was given.

Reporting group title	Group B (Filler): after single treatment

Reporting group description:

Group B received hyaluronic acid filler alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the single treatment was given but before the 1st combined treatment was given.

Reporting group title	Group A: after first combined treatment

Reporting group description:

Group A received Azzalure alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the 1st combined treatment was given.

Reporting group title	Group B: after first combined treatment

Reporting group description:

Group B received hyaluronic acid filler alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the 1st combined treatment was given.

Reporting group title	Group A: after second combined treatment

Reporting group description:

Group A received Azzalure alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the 2nd combined treatment was given.

Reporting group title	Group B: after second combined treatment

Reporting group description:

Group B received hyaluronic acid filler alone as initial single treatment, and thereafter two combined treatments. Events reported in this section occured after the 2nd combined treatment was given.

Serious adverse events	Group A after single treatment with Azzalure	Group B (Filler): after single treatment	Group A: after first combined treatment
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	0 / 28 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Angina pectoris			

subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Group B: after first combined treatment	Group A: after second combined treatment	Group B: after second combined treatment
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Group A after single treatment with Azzalure	Group B (Filler): after single treatment	Group A: after first combined treatment
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 29 (3.45%)	4 / 31 (12.90%)	15 / 28 (53.57%)
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
VII nerve paralysis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	3 / 28 (10.71%)
occurrences (all)	0	1	3
Implant site bruising			

subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	7 / 28 (25.00%)
occurrences (all)	0	0	7
Implant site oedema			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Inflammatory reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Lump			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Swelling			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Skin and subcutaneous tissue disorders			
Skin reaction			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Nephritic colic			
subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Common cold			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Cystitis			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	1 / 29 (3.45%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Sinusitis			

subjects affected / exposed	0 / 29 (0.00%)	1 / 31 (3.23%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Tooth infection			
subjects affected / exposed	0 / 29 (0.00%)	0 / 31 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group B: after first combined treatment	Group A: after second combined treatment	Group B: after second combined treatment
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 28 (46.43%)	9 / 28 (32.14%)	9 / 28 (32.14%)
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
VII nerve paralysis			
subjects affected / exposed	1 / 28 (3.57%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	1 / 28 (3.57%)	2 / 28 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	2	0
Implant site bruising			
subjects affected / exposed	4 / 28 (14.29%)	5 / 28 (17.86%)	4 / 28 (14.29%)
occurrences (all)	4	5	4
Implant site oedema			
subjects affected / exposed	3 / 28 (10.71%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	3	0	0
Inflammatory reaction			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Lump			
subjects affected / exposed	0 / 28 (0.00%)	1 / 28 (3.57%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Swelling			

subjects affected / exposed	1 / 28 (3.57%)	0 / 28 (0.00%)	1 / 28 (3.57%)
occurrences (all)	1	0	1
Skin and subcutaneous tissue disorders			
Skin reaction			
subjects affected / exposed	1 / 28 (3.57%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Nephritic colic			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 28 (3.57%)	1 / 28 (3.57%)	1 / 28 (3.57%)
occurrences (all)	1	1	1
Common cold			
subjects affected / exposed	2 / 28 (7.14%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	2	0	0
Cystitis			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	2 / 28 (7.14%)	0 / 28 (0.00%)	1 / 28 (3.57%)
occurrences (all)	2	0	1
Sinusitis			
subjects affected / exposed	0 / 28 (0.00%)	1 / 28 (3.57%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Tooth infection			
subjects affected / exposed	0 / 28 (0.00%)	0 / 28 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/31592825